Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
If can be difficult to imagine a world suddenly so equitable that in the next four years 90 percent of all people living with HIV have […]
Patients in the highest tuberculosis-burden countries who primarily rely on the private sector for their healthcare needs do not have access to the GeneXpert MTB/RIF diagnostic test […]
Survey responses across 12 countries, six regions show range of awareness, common dangers, failures to communicate . . . On the positive side, two-thirds of a […]
The State Department’s funding document released following the White House budget today shows the Administration proposed the same amount for tuberculosis programs this year as it did last […]